×
0 0 0 0 0 0 0 0
Stock impact report

UroGen Delivers Updated Complete Response (CR) and Durability Data from the UGN-101 Phase 3 OLYMPUS Trial

UroGen Pharma Ltd (URGN)  More Company Research Source: Business Wire
Last urogen pharma ltd earnings: 8/9 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.urogen.com
PDF Complete Response (CR) Rate Consistent at 59 Percent Six-month Durability Strong with 89 Percent of Evaluable Patients Remaining in CR Full Phase 3 Data Anticipated for 2H 2019 NEW YORK--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, today announced findings from a secondary analysis from the pivotal Phase 3 OLYMPUS trial which showed that UGN-101 (mitomycin gel) for instillation, an investigational mitomycin formulation, demonstrated a 59 percent complete response rate in a subset of patients with endoscopically unresectable low-grade upper tract urothelial cancer (UTUC). Findings were presented by Seth Paul Lerner, M.D., FACS, Professor of Urology at Baylor College of Medicine, in an oral presentation during the plenary session at the 114th American Urological Asso [Read more]
Impact snapshot Event time: URGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
URGN alerts
from News Quantified
Opt-in for
URGN alerts

from News Quantified
Opt-in for
URGN alerts

from News Quantified